FGF2 and plasma cell myeloma: Thalidomide shows its various pharmacological actions in angiogenesis, immunomodulation, and anti-tumor actions in multiple myeloma; the mechanism of teratogenicity of thalidomide has been elucidated as the inhibition of cereblon, and its associated ubiquitin ligase activity and inhibition of angiogenesis by inhibiting basic fibroblast growth factor [[50], [51], [52], [53], [54]].